Kathryn N North

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7584063/publications.pdf

Version: 2024-02-01

		4370	9839
412	26,166	86	141
papers	citations	h-index	g-index

439	439	439	22543
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sex- and age-related differences in autistic behaviours in children with neurofibromatosis type 1. Journal of Autism and Developmental Disorders, 2023, 53, 2835-2850.	1.7	2
2	The MMAAS Project: An Observational Human Study Investigating the Effect of Anabolic Androgenic Steroid Use on Gene Expression and the Molecular Mechanism of Muscle Memory. Clinical Journal of Sport Medicine, 2023, 33, e115-e122.	0.9	2
3	The mediating role of ADHD symptoms between executive function and social skills in children with neurofibromatosis type 1. Child Neuropsychology, 2022, 28, 318-336.	0.8	2
4	Loss of Î±-actinin-3 confers protection from eccentric contraction damage in fast-twitch EDL muscles from aged mdx dystrophic mice by reducing pathological fibre branching. Human Molecular Genetics, 2022, 31, 1417-1429.	1.4	2
5	Delineating the autistic phenotype in children with neurofibromatosis type 1. Molecular Autism, 2022, 13, 3.	2.6	8
6	Response to MÃ¶rseburg etÂal.. American Journal of Human Genetics, 2022, 109, 973.	2.6	2
7	Absence of the Z-disc protein Î±-actinin-3 impairs the mechanical stability of Actn3KO mouse fast-twitch muscle fibres without altering their contractile properties or twitch kinetics. Skeletal Muscle, 2022, 12, .	1.9	3
8	Autism in neurofibromatosis type 1: misuse of covariance to dismiss autistic trait burden. Developmental Medicine and Child Neurology, 2021, 63, 233-234.	1.1	4
9	Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. Journal of Attention Disorders, 2021, 25, 1177-1186.	1.5	32
10	Loss of Î±-actinin-3 during human evolution provides superior cold resilience and muscle heat generation. American Journal of Human Genetics, 2021, 108, 446-457.	2.6	32
11	ACTN3 genotype influences skeletal muscle mass regulation and response to dexamethasone. Science Advances, 2021, 7, .	4.7	7
12	Generating an iPSC line (with isogenic control) from the PBMCs of an ACTA1 (p.Gly148Asp) nemaline myopathy patient. Stem Cell Research, 2021, 54, 102429.	0.3	3
13	Dystrophin-negative slow-twitch soleus muscles are not susceptible to eccentric contraction induced injury over the lifespan of the mdx mouse. American Journal of Physiology - Cell Physiology, 2021, 321, C704-C720.	2.1	11
14	Scaling national and international improvement in virtual gene panel curation via a collaborative approach to discordance resolution. American Journal of Human Genetics, 2021, 108, 1551-1557.	2.6	36
15	Profiling the Word Reading Abilities of School-Age Children with Neurofibromatosis Type 1. Journal of the International Neuropsychological Society, 2021, 27, 484-496.	1.2	7
16	GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics, 2021, 1, 100029.	3.0	94
17	Auditory Dysfunction Among Individuals With Neurofibromatosis Type 1. JAMA Network Open, 2021, 4, e2136842.	2.8	3
18	Lifespan Analysis of Dystrophic mdx Fast-Twitch Muscle Morphology and Its Impact on Contractile Function. Frontiers in Physiology, 2021, 12, 771499.	1.3	9

#	Article	IF	Citations
19	A brief history of human disease genetics. Nature, 2020, 577, 179-189.	13.7	441
20	TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy. European Journal of Human Genetics, 2020, 28, 815-825.	1.4	36
21	LATE BREAKING NEWS E-POSTER PRESENTATION. Neuromuscular Disorders, 2020, 30, S170.	0.3	0
22	Isolated Extensor Digitorum Longus Muscles from Old mdx Dystrophic Mice Show Little Force Recovery 120 Minutes after Eccentric Damage. Biophysical Journal, 2020, 118, 121a.	0.2	0
23	Generation of four iPSC lines from Neurofibromatosis Type 1 patients. Stem Cell Research, 2020, 49, 102013.	0.3	1
24	Eosinophil function in adipose tissue is regulated by KrÃ¼ppel-like factor 3 (KLF3). Nature Communications, 2020, 11, 2922.	5.8	35
25	Social skills and autism spectrum disorder symptoms in children with neurofibromatosis type 1: evidence for clinical trial outcomes. Developmental Medicine and Child Neurology, 2020, 62, 813-819.	1.1	13
26	Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. Annals of Clinical and Translational Neurology, 2020, 7, 245-249.	1.7	9
27	Attention to faces in social context in children with neurofibromatosis type 1. Developmental Medicine and Child Neurology, 2019, 61, 174-180.	1.1	11
28	Australian Genomics: A Federated Model for Integrating Genomics into Healthcare. American Journal of Human Genetics, 2019, 105, 7-14.	2.6	75
29	A â€œhuman knockoutâ€•model to investigate the influence of the Î±-actinin-3 protein on exercise-induced mitochondrial adaptations. Scientific Reports, 2019, 9, 12688.	1.6	13
30	Building a learning community of Australian clinical genomics: a social network study of the Australian Genomic Health Alliance. BMC Medicine, 2019, 17, 44.	2.3	22
31	A transformative translational change programme to introduce genomics into healthcare: a complexity and implementation science study protocol. BMJ Open, 2019, 9, e024681.	0.8	21
32	Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study. BMJ Open, 2019, 9, e030601.	0.8	11
33	Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Annals of Clinical and Translational Neurology, 2019, 6, 2555-2565.	1.7	24
34	Integrating Genomics into Healthcare: A Global Responsibility. American Journal of Human Genetics, 2019, 104, 13-20.	2.6	264
35	Preliteracy impairments in children with neurofibromatosis type 1. Developmental Medicine and Child Neurology, 2018, 60, 703-710.	1.1	15
36	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	2.8	93

#	Article	IF	Citations
37	Monitoring of optic nerve function in Neurofibromatosis 2 children with optic nerve sheath meningiomas using multifocal visual evoked potentials. Journal of Clinical Neuroscience, 2018, 50, 262-267.	0.8	5
38	Nemaline myopathy and distal arthrogryposis associated with an autosomal recessiveÂTNNT3 Âsplice variant. Human Mutation, 2018, 39, 383-388.	1.1	48
39	The Effect of ACTN3 Gene Doping on Skeletal Muscle Performance. American Journal of Human Genetics, 2018, 102, 845-857.	2.6	17
40	Impaired engagement of the ventral attention system in neurofibromatosis type 1. Brain Imaging and Behavior, 2018, 12, 499-508.	1.1	12
41	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	1.5	148
42	Is evolutionary loss our gain? The role of ACTN3 p.Arg577Ter (R577X) genotype in athletic performance, ageing, and disease. Human Mutation, 2018, 39, 1774-1787.	1.1	50
43	Branched fibers from old fast-twitch dystrophic muscles are the sites of terminal damage in muscular dystrophy. American Journal of Physiology - Cell Physiology, 2018, 314, C662-C674.	2.1	23
44	Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial. BMJ Open, 2018, 8, e021800.	0.8	12
45	No association between ACTN3 R577X and ACE I/D polymorphisms and endurance running times in 698 Caucasian athletes. BMC Genomics, 2018, 19, 13.	1.2	65
46	Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis. Neuropsychology Review, 2018, 28, 317-340.	2.5	45
47	The relationship between deficit in digit span and genotype in nonsense mutation Duchenne muscular dystrophy. Neurology, 2018, 91, e1215-e1219.	1.5	12
48	Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy. Nature Communications, 2017, 8, 14143.	5.8	58
49	Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Science Translational Medicine, 2017, 9, .	5.8	516
50	Can in-the-moment diary methods measure health-related quality of life in Duchenne muscular dystrophy?. Quality of Life Research, 2017, 26, 1145-1152.	1.5	8
51	Atypical Local Interference Affects Global Processing in Children with Neurofibromatosis Type 1. Journal of the International Neuropsychological Society, 2017, 23, 446-450.	1.2	3
52	The neural basis of deficient response inhibition in children with neurofibromatosis type 1: Evidence from a functional MRI study. Cortex, 2017, 93, 1-11.	1.1	14
53	Exploring the relationship between Î±-actinin-3 deficiency and obesity in mice and humans. International Journal of Obesity, 2017, 41, 1154-1157.	1.6	9
54	Clinical characterisation of a large international congenital titinopathy cohort. Neuromuscular Disorders, 2017, 27, S37.	0.3	0

#	Article	IF	Citations
55	Androgen Action via the Androgen Receptor in Neurons Within the Brain Positively Regulates Muscle Mass in Male Mice. Endocrinology, 2017, 158, 3684-3695.	1.4	26
56	Do titin developmental isoforms contribute to the pathogenesis of congenital titinopathy?. Neuromuscular Disorders, 2017, 27, S237-S238.	0.3	1
57	Large-scale GWAS identifies multiple loci for hand grip strength providing biological insights into muscular fitness. Nature Communications, 2017, 8, 16015.	5.8	149
58	Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases. Npj Genomic Medicine, 2017, 2, .	1.7	67
59	Neurofibromatosis Type 2. Journal of Child Neurology, 2017, 32, 9-22.	0.7	75
60	The kids are OK: it is discrimination not sameâ€sex parents that harms children. Medical Journal of Australia, 2017, 207, 374-375.	0.8	13
61	Facial emotion recognition, face scan paths, and face perception in children with neurofibromatosis type 1.. Neuropsychology, 2017, 31, 361-370.	1.0	13
62	Social Competence in Children with Neurofibromatosis Type 1: Relationships with Psychopathology and Cognitive Ability. Journal of Childhood & Developmental Disorders, 2016, 02, .	0.3	7
63	No Evidence of a Common DNA Variant Profile Specific to World Class Endurance Athletes. PLoS ONE, 2016, 11, e0147330.	1.1	96
64	Uptake of health monitoring and disease selfâ€management in Australian adults with neurofibromatosis type 1: strategies to improve care. Clinical Genetics, 2016, 89, 385-391.	1.0	6
65	The Effect of Heterozygosity for the ACTN3 Null Allele on Human Muscle Performance. Medicine and Science in Sports and Exercise, 2016, 48, 509-520.	0.2	14
66	Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases. Journal of Neuromuscular Diseases, 2016, 3, 209-225.	1.1	18
67	TOR1AIP1 as a cause of cardiac failure and recessive limb-girdle muscular dystrophy. Neuromuscular Disorders, 2016, 26, 500-503.	0.3	38
68	ACTN3 R577X and ACE I/D gene variants influence performance in elite sprinters: a multi-cohort study. BMC Genomics, 2016, 17, 285.	1.2	106
69	Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology, 2016, 87, S4-S12.	1.5	36
70	Phonics Training Improves Reading in Children with Neurofibromatosis Type 1: A Prospective Intervention Trial. Journal of Pediatrics, 2016, 177, 219-226.e2.	0.9	10
71	Neurocognitive outcomes in neurofibromatosis clinical trials. Neurology, 2016, 87, S21-30.	1.5	16
72	Variants in SLC18A3 , vesicular acetylcholine transporter, cause congenital myasthenic syndrome. Neurology, 2016, 87, 1442-1448.	1.5	46

#	Article	IF	Citations
73	Variants in the Oxidoreductase PYROXD1 Cause Early-Onset Myopathy with Internalized Nuclei and Myofibrillar Disorganization. American Journal of Human Genetics, 2016, 99, 1086-1105.	2.6	45
74	Analysis of a large international cohort confirms that recessively inherited loss-of-function TTN mutations cause prenatal or infant-onset muscle disease, often complicated by early cardiorespiratory involvement. Neuromuscular Disorders, 2016, 26, S89.	0.3	0
75	Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology, 2016, 87, S40-8.	1.5	23
76	Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. Neurology, 2016, 87, S13-20.	1.5	15
77	Current whole-body MRI applications in the neurofibromatoses. Neurology, 2016, 87, S31-9.	1.5	65
78	Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology, 2016, 87, 2575-2584.	1.5	76
79	Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1. JAMA Psychiatry, 2016, 73, 1276.	6.0	90
80	Theory of mind in children with Neurofibromatosis Type 1.. Neuropsychology, 2016, 30, 439-448.	1.0	27
81	A federated ecosystem for sharing genomic, clinical data. Science, 2016, 352, 1278-1280.	6.0	175
82	The Future of Genomic Research in Athletic Performance and Adaptation to Training. Medicine and Sport Science, 2016, 61, 55-67.	1.4	35
83	Diagnosis and etiology of congenital muscular dystrophy: We are halfway there. Annals of Neurology, 2016, 80, 101-111.	2.8	57
84	Lack of MG53 in human heart precludes utility as a biomarker of myocardial injury or endogenous cardioprotective factor. Cardiovascular Research, 2016, 110, 178-187.	1.8	46
85	How does Î±-actinin-3 deficiency alter muscle function? Mechanistic insights into ACTN3 , the â€˜gene for speedâ€™. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 686-693.	1.9	57
86	Prominent scapulae mimicking an inherited myopathy expands the phenotype of CHD7-related disease. European Journal of Human Genetics, 2016, 24, 1216-1219.	1.4	2
87	Rodent models for resolving extremes of exercise and health. Physiological Genomics, 2016, 48, 82-92.	1.0	20
88	Athlome Project Consortium: a concerted effort to discover genomic and other â€œomicâ€•markers of athletic performance. Physiological Genomics, 2016, 48, 183-190.	1.0	96
89	Mutations in HSPB8 causing a new phenotype of distal myopathy and motor neuropathy. Neurology, 2016, 86, 391-398.	1.5	107
90	Analysis of theACTN3heterozygous genotype suggests that Î±-actinin-3 controls sarcomeric composition and muscle function in a dose-dependent fashion. Human Molecular Genetics, 2016, 25, 866-877.	1.4	35

#	Article	IF	Citations
91	TREAT-NMD (translational research in Europe, assessment and treatment for neuromuscular) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.3	0
92	Associate Professor Nigel Clarke PhD, MBChB, FRACP (1966â€“2015). Neuromuscular Disorders, 2015, 25, 977-978.	0.3	0
93	Muscle weakness in children with neurofibromatosis type 1. Developmental Medicine and Child Neurology, 2015, 57, 733-736.	1.1	21
94	Direct-to-consumer genetic testing for predicting sports performance and talent identification: Consensus statement. British Journal of Sports Medicine, 2015, 49, 1486-1491.	3.1	113
95	Recessive ACTA1 variant causes congenital muscular dystrophy with rigid spine. European Journal of Human Genetics, 2015, 23, 883-886.	1.4	23
96	Altered Ca2+ Kinetics Associated with Î±-Actinin-3 Deficiency May Explain Positive Selection for ACTN3 Null Allele in Human Evolution. PLoS Genetics, 2015, 11, e1004862.	1.5	39
97	Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy. Neurology, 2015, 84, 1369-1378.	1.5	88
98	Congenital and Other Structural Myopathies. , 2015, , 499-537.		3
99	The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults. Journal of Genetic Counseling, 2015, 24, 931-944.	0.9	33
100	Expanding the phenotype of GMPPB mutations. Brain, 2015, 138, 836-844.	3.7	54
101	Developmental Trajectories of Young Children with Neurofibromatosis Type 1: A Longitudinal Study from 21 to 40ÂMonths of Age. Journal of Pediatrics, 2015, 166, 1006-1012.e1.	0.9	18
102	All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. Cancer Discovery, 2015, 5, 1133-1136.	7.7	45
103	Reply: The p.Ser107Leu inBICD2is a mutation â€˜hot spotâ€™ causing distal spinal muscular atrophy. Brain, 2015, 138, e392-e392.	3.7	1
104	Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology, 2015, 85, 1432-1433.	1.5	3
105	Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy. JAMA Neurology, 2015, 72, 1424.	4.5	164
106	Mutations inPIGY: expanding the phenotype of inherited glycosylphosphatidylinositol deficiencies. Human Molecular Genetics, 2015, 24, 6146-6159.	1.4	64
107	Muscle weakness inTPM3-myopathy is due to reduced Ca²⁺-sensitivity and impaired acto-myosin cross-bridge cycling in slow fibres. Human Molecular Genetics, 2015, 24, 6278-6292.	1.4	38
108	A gene for speed: The influence of ACTN3 on muscle performance in health and disease. Neuromuscular Disorders, 2015, 25, S185.	0.3	0

#	Article	IF	Citations
109	Mutated HSPB8 causes both neurogenic and myopathic disease with muscle proteinopathy. Neuromuscular Disorders, 2015, 25, S256.	0.3	0
110	Phenotypic and molecular insights into spinal muscular atrophy due to mutations in BICD2. Brain, 2015, 138, 293-310.	3.7	82
111	Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies. Neuromuscular Disorders, 2015, 25, 43-54.	0.3	30
112	LMOD3: the â€œmissing linkâ€•in nemaline myopathy?. Oncotarget, 2015, 6, 26548-26549.	0.8	11
113	Î±â€•actininâ€3 deficiency is associated with increased exercise performance and trainingâ€•induced changes in mitochondrial respiration in humans. FASEB Journal, 2015, 29, 677.27.	0.2	0
114	NF1 is a critical regulator of muscle development and metabolism. Human Molecular Genetics, 2014, 23, 1250-1259.	1.4	40
115	Activating internal ribosome entry to treat Duchenne muscular dystrophy. Nature Medicine, 2014, 20, 987-988.	15.2	3
116	Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1. Developmental Medicine and Child Neurology, 2014, 56, 468-474.	1.1	39
117	Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 2014, 50, 477-487.	1.0	357
118	Mutation Update: The Spectra of Nebulin Variants and Associated Myopathies. Human Mutation, 2014, 35, 1418-1426.	1.1	107
119	The genetic and neuroanatomical basis of social dysfunction: Lessons from neurofibromatosis type 1. Human Brain Mapping, 2014, 35, 2372-2382.	1.9	30
120	Longitudinal assessment of cognition and T2â€•hyperintensities in NF1: An 18â€•year study. American Journal of Medical Genetics, Part A, 2014, 164, 661-665.	0.7	41
121	Î±-Actinin-3 deficiency alters muscle adaptation in response to denervation and immobilization. Human Molecular Genetics, 2014, 23, 1879-1893.	1.4	26
122	Sequence analysis of the equine ACTN3 gene in Australian horse breeds. Gene, 2014, 538, 88-93.	1.0	12
123	Mutation Update and Genotype-Phenotype Correlations of Novel and Previously Described Mutations inTPM2andTPM3Causing Congenital Myopathies. Human Mutation, 2014, 35, 779-790.	1.1	92
124	G.O.2. Neuromuscular Disorders, 2014, 24, 792-793.	0.3	1
125	G.P.219. Neuromuscular Disorders, 2014, 24, 882-883.	0.3	0
126	G.P.35. Neuromuscular Disorders, 2014, 24, 805.	0.3	1

#	Article	IF	Citations
127	G.P.271. Neuromuscular Disorders, 2014, 24, 898.	0.3	0
128	Calpain cleavage within dysferlin exon 40a releases a synaptotagmin-like module for membrane repair. Molecular Biology of the Cell, 2014, 25, 3037-3048.	0.9	62
129	Approach to the diagnosis of congenital myopathies. Neuromuscular Disorders, 2014, 24, 97-116.	0.3	239
130	Diagnostic approach to the congenital muscular dystrophies. Neuromuscular Disorders, 2014, 24, 289-311.	0.3	275
131	Genetics and sport performance: current challenges and directions to the future. Revista Brasileira De EducaÃ§Ã£o FÃsica E Esporte: RBEFE, 2014, 28, 177-193.	0.1	28
132	Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy. Journal of Clinical Investigation, 2014, 124, 4693-4708.	3.9	153
133	Evidence Based Selection of Commonly Used RT-qPCR Reference Genes for the Analysis of Mouse Skeletal Muscle. PLoS ONE, 2014, 9, e88653.	1.1	69
134	A novel mutation expands the genetic and clinical spectrum of MYH7-related myopathies. Neuromuscular Disorders, 2013, 23, 432-436.	0.3	35
135	Calpains, Cleaved Mini-Dysferlin_{C72}, and L-Type Channels Underpin Calcium-Dependent Muscle Membrane Repair. Journal of Neuroscience, 2013, 33, 5085-5094.	1.7	93
136	Identification of KLHL41 Mutations Implicates BTB-Kelch-Mediated Ubiquitination as an Alternate Pathway to Myofibrillar Disruption in Nemaline Myopathy. American Journal of Human Genetics, 2013, 93, 1108-1117.	2.6	147
137	Mutations in KLHL40 Are a Frequent Cause of Severe Autosomal-Recessive Nemaline Myopathy. American Journal of Human Genetics, 2013, 93, 6-18.	2.6	186
138	Social functioning in adults with neurofibromatosis type 1. Research in Developmental Disabilities, 2013, 34, 3393-3399.	1.2	29
139	Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials. Journal of Neurology, 2013, 260, 214-220.	1.8	26
140	Corrigendum to â€œThe Learning Disabilities Network (LeaDNet): Using Neurofibromatosis Type 1 [NF1] as a Paradigm for Translational Researchâ€• , 2013, 161, 236-236.		0
141	P.1.2 Natural history of pulmonary function in collagen VI-related myopathies: An international study. Neuromuscular Disorders, 2013, 23, 741-742.	0.3	0
142	Mutations in GDP-Mannose Pyrophosphorylase B Cause Congenital and Limb-Girdle Muscular Dystrophies Associated with Hypoglycosylation of Î±-Dystroglycan. American Journal of Human Genetics, 2013, 93, 29-41.	2.6	197
143	Mutations in BICD2 Cause Dominant Congenital Spinal Muscular Atrophy and Hereditary Spastic Paraplegia. American Journal of Human Genetics, 2013, 92, 965-973.	2.6	156
144	P.10.21 Next-generation sequencing meets genetic diagnostics: Development of a comprehensive workflow for neuromuscular disorders. Neuromuscular Disorders, 2013, 23, 795.	0.3	0

#	Article	IF	Citations
145	O.10 Mutations in a new dynein/dynactin adaptor gene cause Dominant Congenital Spinal Muscular Atrophy (DCSMA) and Hereditary Spastic Paraplegia (HSP). Neuromuscular Disorders, 2013, 23, 798.	0.3	0
146	O.18 Systematic identification of causal mutations in Mendelian disorders using exome sequence data. Neuromuscular Disorders, 2013, 23, 850.	0.3	0
147	Cognitive Features that Distinguish Preschool-Age Children with Neurofibromatosis Type 1 from Their Peers: A Matched Case-Control Study. Journal of Pediatrics, 2013, 163, 1479-1483.e1.	0.9	26
148	P.9.4. Neuromuscular Disorders, 2013, 23, 784.	0.3	0
149	Genes for Elite Power and Sprint Performance: ACTN3 Leads the Way. Sports Medicine, 2013, 43, 803-817.	3.1	158
150	Natural history of pulmonary function in collagen VI-related myopathies. Brain, 2013, 136, 3625-3633.	3.7	85
151	K7del is a common TPM2 gene mutation associated with nemaline myopathy and raised myofibre calcium sensitivity. Brain, 2013, 136, 494-507.	3.7	42
152	ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling. Journal of Clinical Investigation, 2013, 123, 4255-4263.	3.9	113
153	Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge. American Journal of Medical Genetics, Part A, 2013, 161, 659-666.	0.7	26
154	Association Analysis of ACE and ACTN3 in Elite Caucasian and East Asian Swimmers. Medicine and Science in Sports and Exercise, 2013, 45, 892-900.	0.2	80
155	ACTN3 Allele Frequency in Humans Covaries with Global Latitudinal Gradient. PLoS ONE, 2013, 8, e52282.	1.1	29
156	A procedure for the computerized analysis of cleft palate speech transcription. Clinical Linguistics and Phonetics, 2012, 26, 18-38.	0.5	0
157	Importance and challenge of making an early diagnosis in LMNA -related muscular dystrophy. Neurology, 2012, 78, 1258-1263.	1.5	41
158	Autosomal dominant congenital spinal muscular atrophy: a true form of spinal muscular atrophy caused by early loss of anterior horn cells. Brain, 2012, 135, 1714-1723.	3.7	21
159	Does attentionâ€deficitâ€“hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1?. Developmental Medicine and Child Neurology, 2012, 54, 898-904.	1.1	43
160	Consensus Statement on Standard of Care for Congenital Myopathies. Journal of Child Neurology, 2012, 27, 363-382.	0.7	147
161	Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas. Familial Cancer, 2012, 11, 653-656.	0.9	7
162	Sniff nasal inspiratory pressure and sleep disordered breathing in childhood neuromuscular disorders. Neuromuscular Disorders, 2012, 22, 528-533.	0.3	19

#	Article	IF	Citations
163	The Impact of ADHD on the Cognitive and Academic Functioning of Children With NF1. Developmental Neuropsychology, 2012, 37, 590-600.	1.0	65
164	Treatment for plexiform neurofibromas in patients with NF1. Lancet Oncology, The, 2012, 13, 1175-1176.	5.1	4
165	Mutations in TPM2 and congenital fibre type disproportion. Neuromuscular Disorders, 2012, 22, 955-958.	0.3	21
166	G.P.41 The identification of LGMD2G (TCAP) in Australia. Neuromuscular Disorders, 2012, 22, 831-832.	0.3	12
167	G.P.46 Screening for deletion and duplication mutations in genes implicated in LGMD. Neuromuscular Disorders, 2012, 22, 833.	0.3	0
168	C.I.1 Gene Wars: Episode V. The clinician strikes back. Neuromuscular Disorders, 2012, 22, 838.	0.3	0
169	C.P.15 K7del is a recurrent TPM2 nemaline myopathy mutation associated with joint contractures and increased calcium sensitivity. Neuromuscular Disorders, 2012, 22, 845.	0.3	0
170	S.P.53 Interventions for increasing ankle flexibility in patients with neuromuscular disease: A Cochrane Systematic Review. Neuromuscular Disorders, 2012, 22, 885.	0.3	0
171	S.P.55 Transition and outcomes for young men with Duchenne muscular dystrophy in New South Wales. Neuromuscular Disorders, 2012, 22, 885-886.	0.3	1
172	S.P.21 Clinical outcome measures in Collagen 6 (COL6) and Laminin Î±2(LAMA2) related congenital muscular dystrophy. Neuromuscular Disorders, 2012, 22, 893.	0.3	0
173	RARE MYOPATHIES AND EXPERIMENTAL APPROACHES - POSTER PRESENTATIONS G.P.125 ACTN3 genotype influences skeletal muscle performance through alterations in calcineurin signaling. Neuromuscular Disorders, 2012, 22, 904.	0.3	0
174	Clinical utility gene card for: Centronuclear and myotubular myopathies. European Journal of Human Genetics, 2012, 20, 1101-1101.	1.4	28
175	The Learning Disabilities Network (LeaDNet): Using neurofibromatosis type 1 (NF1) as a paradigm for translational research. American Journal of Medical Genetics, Part A, 2012, 158A, 2225-2232.	0.7	29
176	Ferlins: Regulators of Vesicle Fusion for Auditory Neurotransmission, Receptor Trafficking and Membrane Repair. Traffic, 2012, 13, 185-194.	1.3	119
177	Inherited neuromuscular disorders: Pathway to diagnosis. Journal of Paediatrics and Child Health, 2012, 48, 458-465.	0.4	19
178	The Cognitive Profile of NF1 Children: Therapeutic Implications. , 2012, , 55-69.		7
179	Children with Neurofi bromatosis Type 1: Positron Emission Tomography. Pediatric Cancer, 2012, , 99-105.	0.0	0
180	Fetal akinesia: review of the genetics of the neuromuscular causes. Journal of Medical Genetics, 2011, 48, 793-801.	1.5	65

#	Article	IF	Citations
181	Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior. Child Neuropsychology, 2011, 17, 313-329.	0.8	131
182	Î±-Actinin-3 deficiency is associated with reduced bone mass in human and mouse. Bone, 2011, 49, 790-798.	1.4	37
183	Altered cellular localization of aquaporin-1 in experimental hydrocephalus in mice and reduced ventriculomegaly in aquaporin-1 deficiency. Molecular and Cellular Neurosciences, 2011, 46, 318-324.	1.0	28
184	Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies. Neuromuscular Disorders, 2011, 21, 194-203.	0.3	16
185	A study of FHL1, BAG3, MATR3, PTRF and TCAP in Australian muscular dystrophy patients. Neuromuscular Disorders, 2011, 21, 776-781.	0.3	13
186	P5.63. RNAlaterÂ® simplifies the transport of muscle sections for mRNA analysis over long distances. Neuromuscular Disorders, 2011, 21, 743.	0.3	0
187	P2.5 The identification of a viable outcome measure in the collagen VI myopathies promotes progress toward clinical trials. Neuromuscular Disorders, 2011, 21, 662.	0.3	0
188	P3.27 Childhood mitochondrial neuropathies: Clinical, electrophysiological and histopathological characteristics. Neuromuscular Disorders, 2011, 21, 690.	0.3	0
189	P3.32 The molecular genetics of monogenic neuromuscular disorders characterised by reduced foetal movement. Neuromuscular Disorders, 2011, 21, 691.	0.3	2
190	P3.37 New histopathlogical features in Centronuclear Myopathy caused by DNM2 mutations â€“ clues to disease pathogenesis. Neuromuscular Disorders, 2011, 21, 693.	0.3	0
191	P3.51 A new form of autosomal recessive myopathy associated with male hypogonadism links to chromosome 11q. Neuromuscular Disorders, 2011, 21, 697-698.	0.3	0
192	Mild Functional Differences of Dynamin 2 Mutations Associated to Centronuclear Myopathy and Charcot-Marie-Tooth Peripheral Neuropathy. PLoS ONE, 2011, 6, e27498.	1.1	40
193	Dysferlin, Annexin A1, and Mitsugumin 53 Are Upregulated in Muscular Dystrophy and Localize to Longitudinal Tubules of the T-System With Stretch. Journal of Neuropathology and Experimental Neurology, 2011, 70, 302-313.	0.9	77
194	Loss of IL-15 receptor Î± alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles. Journal of Clinical Investigation, 2011, 121, 3120-3132.	3.9	72
195	Health status of boys with Duchenne muscular dystrophy: A parent's perspective. Journal of Paediatrics and Child Health, 2011, 47, 557-562.	0.4	27
196	Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. International Journal of Experimental Pathology, 2011, 92, 57-65.	0.6	70
197	Clinical Approach to the Diagnosis of Congenital Myopathies. Seminars in Pediatric Neurology, 2011, 18, 216-220.	1.0	47
198	Mental, Motor, and Language Development of Toddlers with Neurofibromatosis Type 1. Journal of Pediatrics, 2011, 158, 660-665.	0.9	58

#	Article	IF	Citations
199	The effect of Î±-actinin-3 deficiency on muscle aging. Experimental Gerontology, 2011, 46, 292-302.	1.2	47
200	Dominant Mutations in KBTBD13, a Member of the BTB/Kelch Family, Cause Nemaline Myopathy with Cores. American Journal of Human Genetics, 2011, 88, 122.	2.6	0
201	Therapeutics for Childhood Neurofibromatosis Type 1 and Type 2. Current Treatment Options in Neurology, 2011, 13, 529-543.	0.7	20
202	Properties of extensor digitorum longus muscle and skinned fibers from adult and aged male and female Actn3 knockout mice. Muscle and Nerve, 2011, 43, 37-48.	1.0	26
203	Epidermolysis bullosa with lateâ€onset muscular dystrophy and plectin deficiency. Muscle and Nerve, 2011, 44, 135-141.	1.0	16
204	Using complementary DNA from MyoDâ€transduced fibroblasts to sequence large muscle genes. Muscle and Nerve, 2011, 44, 280-282.	1.0	3
205	Deficiency of Î±-actinin-3 is associated with increased susceptibility to contraction-induced damage and skeletal muscle remodeling. Human Molecular Genetics, 2011, 20, 2914-2927.	1.4	95
206	Hypertrophy and dietary tyrosine ameliorate the phenotypes of a mouse model of severe nemaline myopathy. Brain, 2011, 134, 3516-3529.	3.7	59
207	In Vitro Analysis of Rod Composition and Actin Dynamics in Inherited Myopathies. Journal of Neuropathology and Experimental Neurology, 2010, 69, 429-441.	0.9	24
208	Dominant Mutations in KBTBD13, a Member of the BTB/Kelch Family, Cause Nemaline Myopathy with Cores. American Journal of Human Genetics, 2010, 87, 842-847.	2.6	143
209	Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1309-1317.	3.3	45
210	Phylogenetic analysis of ferlin genes reveals ancient eukaryotic origins. BMC Evolutionary Biology, 2010, 10, 231.	3.2	49
211	Are biological sensors modulated by their structural scaffolds? The role of the structural muscle proteins Iâ€actininâ€2 and Iâ€actininâ€3 as modulators of biological sensors. FEBS Letters, 2010, 584, 2974-2980.	1.3	22
212	Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Human Mutation, 2010, 31, E1544-E1550.	1.1	153
213	The evolution of skeletal muscle performance: gene duplication and divergence of human sarcomeric Iâ€actinins. BioEssays, 2010, 32, 17-25.	1.2	31
214	ACTN3 and ACE Genotypes in Elite Jamaican and US Sprinters. Medicine and Science in Sports and Exercise, 2010, 42, 107-112.	0.2	120
215	Reduced Plasma Membrane Expression of Dysferlin Mutants Is Attributed to Accelerated Endocytosis via a Syntaxin-4-associated Pathway. Journal of Biological Chemistry, 2010, 285, 28529-28539.	1.6	37
216	Factors Associated With Foot and Ankle Strength in Healthy Preschool-Age Children and Age-Matched Cases of Charcot-Marie-Tooth Disease Type 1A. Journal of Child Neurology, 2010, 25, 463-468.	0.7	31

#	Article	IF	Citations
217	Brain structure and function in neurofibromatosis type 1: current concepts and future directions. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 304-309.	0.9	90
218	The Cognitive Profile of Preschool-Aged Children with Neurofibromatosis Type 1. Child Neuropsychology, 2010, 17, 1-16.	0.8	30
219	Health-related Quality of Life in Boys With Duchenne Muscular Dystrophy: Agreement Between Parents and Their Sons. Journal of Child Neurology, 2010, 25, 1188-1194.	0.7	55
220	A Gene for Speed: The Emerging Role of Î±-Actinin-3 in Muscle Metabolism. Physiology, 2010, 25, 250-259.	1.6	95
221	Collagen VI Microfibril Formation Is Abolished by an Î±2(VI) von Willebrand Factor Type A Domain Mutation in a Patient with Ullrich Congenital Muscular Dystrophy. Journal of Biological Chemistry, 2010, 285, 33567-33576.	1.6	18
222	Phylogenetic Analysis of Gene Structure and Alternative Splicing in Â-Actinins. Molecular Biology and Evolution, 2010, 27, 773-780.	3.5	15
223	Feasibility of a Computerized Method to Measure Quality of â€œEverydayâ€•Life in Children with Neuromuscular Disorders. Physical and Occupational Therapy in Pediatrics, 2010, 30, 43-53.	0.8	13
224	Serial night casting increases ankle dorsiflexion range in children and young adults with Charcot-Marie-Tooth disease: a randomised trial. Journal of Physiotherapy, 2010, 56, 113-119.	0.7	34
225	Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy. Neuromuscular Disorders, 2010, 20, 229-237.	0.3	100
226	Evidence for a dominant negative disease mechanism in cap myopathy due to TPM3. Neuromuscular Disorders, 2010, 20, 464-466.	0.3	23
227	Validation of an automated computational method for skeletal muscle fibre morphometry analysis. Neuromuscular Disorders, 2010, 20, 540-547.	0.3	25
228	P1.23 Muscle membrane repair proteins are upregulated in muscular dystrophy and localise to t-tubule membranes following mechanical stretch. Neuromuscular Disorders, 2010, 20, 607.	0.3	0
229	P1.41 Recurrent mutations in TPM3 likely arise from gene conversion events linked to multiple Tm5NM1 pseudogenes in the genome. Neuromuscular Disorders, 2010, 20, 613.	0.3	0
230	O.12 A new member of the BTB/Kelch family of proteins is mutated in nemaline myopathy type 6 (NEM6). Neuromuscular Disorders, 2010, 20, 638.	0.3	0
231	Corpus Callosum Morphology and Its Relationship to Cognitive Function in Neurofibromatosis Type 1. Journal of Child Neurology, 2010, 25, 834-841.	0.7	69
232	Interventions for increasing ankle range of motion in patients with neuromuscular disease. The Cochrane Library, 2010, , CD006973.	1.5	26
233	Î±-Actinin-3 deficiency results in reduced glycogen phosphorylase activity and altered calcium handling in skeletal muscle. Human Molecular Genetics, 2010, 19, 1335-1346.	1.4	73
234	Sarcomeric Î±-actinins and their role in human muscle disease. Future Neurology, 2009, 4, 731-743.	0.9	11

#	Article	IF	Citations
235	MURC/Cavin-4 and cavin family members form tissue-specific caveolar complexes. Journal of Cell Biology, 2009, 185, 1259-1273.	2.3	243
236	Myocardial membrane injury in pediatric cardiac surgery: An animal model. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 1154-1162.	0.4	9
237	Dysfunction induced by ischemia versus edema: Does edema matter?. Journal of Thoracic and Cardiovascular Surgery, 2009, 138, 141-147.e1.	0.4	22
238	Myoblast sensitivity and fibroblast insensitivity to osteogenic conversion by BMP-2 correlates with the expression of Bmpr-1a. BMC Musculoskeletal Disorders, 2009, 10, 51.	0.8	30
239	Relationship between foot strength and motor function in preschool-age children. Neuromuscular Disorders, 2009, 19, 104-107.	0.3	16
240	Cap disease due to mutation of the beta-tropomyosin gene (TPM2). Neuromuscular Disorders, 2009, 19, 348-351.	0.3	43
241	G.O.4 Î±-Actinin-3 regulates muscle glycogen phosphorylase: A potential mechanism for the metabolic consequences of the common human null allele of ACTN3. Neuromuscular Disorders, 2009, 19, 545-546.	0.3	1
242	G.P.1.05 RYR1 is a common cause of congenital fibre type disproportion with ptosis, ophthalmoplegia, scoliosis and pronounced axial muscle weakness. Neuromuscular Disorders, 2009, 19, 557.	0.3	1
243	G.P.9.08 Insights into the pathological basis of autosomal dominant distal spinal muscular atrophy from a large Australian family. Neuromuscular Disorders, 2009, 19, 596-597.	0.3	0
244	Neurofibromatosis type 1. Journal of the American Academy of Dermatology, 2009, 61, 1-14.	0.6	443
245	α-Actinin-3 and Performance. Medicine and Sport Science, 2009, 54, 88-101.	1.4	65
246	Changes in skeletal muscle expression of AQP1 and AQP4 in dystrophinopathy and dysferlinopathy patients. Acta Neuropathologica, 2008, 116, 235-246.	3.9	27
247	Reliability of quantifying foot and ankle muscle strength in very young children. Muscle and Nerve, 2008, 37, 626-631.	1.0	36
248	Tropomyosin 4 defines novel filaments in skeletal muscle associated with muscle remodelling/regeneration in normal and diseased muscle. Cytoskeleton, 2008, 65, 73-85.	4.4	39
249	Mutations in TPM3 are a common cause of congenital fiber type disproportion. Annals of Neurology, 2008, 63, 329-337.	2.8	152
250	Collagen VI glycine mutations: Perturbed assembly and a spectrum of clinical severity. Annals of Neurology, 2008, 64, 294-303.	2.8	61
251	Brain involvement in muscular dystrophies with defective dystroglycan glycosylation. Annals of Neurology, 2008, 64, 573-582.	2.8	172
252	Mutations in Contactin-1, a Neural Adhesion and Neuromuscular Junction Protein, Cause a Familial Form of Lethal Congenital Myopathy. American Journal of Human Genetics, 2008, 83, 714-724.	2.6	72

#	Article	IF	Citations
253	Myocardial ischemia is more important than the effects of cardiopulmonary bypass on myocardial water handling and postoperative dysfunction: A pediatric animal model. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 1265-1273.e2.	0.4	29
254	Limbâ€“girdle muscular dystrophy: Diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscular Disorders, 2008, 18, 34-44.	0.3	99
255	Whatâ€™s new in congenital myopathies?. Neuromuscular Disorders, 2008, 18, 433-442.	0.3	55
256	Exclusion of biglycan mutations in a cohort of patients with neuromuscular disorders. Neuromuscular Disorders, 2008, 18, 606-609.	0.3	5
257	G.O.3 Mutations in contactin-1, a neuronal cell adhesion molecule expressed at the neuromuscular junction, cause a novel form of congenital lethal myopathy. Neuromuscular Disorders, 2008, 18, 726.	0.3	0
258	T.P.1.10 Reliability and validity of measuring foot and ankle muscle strength in very young children. Neuromuscular Disorders, 2008, 18, 741-742.	0.3	2
259	T.P.1.14 Interventions for increasing ankle flexibility in patients with neuromuscular disease: A Cochrane systematic review. Neuromuscular Disorders, 2008, 18, 743.	0.3	0
260	G.P.13.03 Mechanisms of rod formation in disease. Neuromuscular Disorders, 2008, 18, 807-808.	0.3	0
261	Muscular dystrophy associated with Î±-dystroglycan deficiency in Sphynx and Devon Rex cats. Neuromuscular Disorders, 2008, 18, 942-952.	0.3	36
262	Hand involvement in children with Charcotâ€“Marie-Tooth disease type 1A. Neuromuscular Disorders, 2008, 18, 970-973.	0.3	44
263	Dietary L-Tyrosine Supplementation in Nemaline Myopathy. Journal of Child Neurology, 2008, 23, 609-613.	0.7	58
264	Diagnosis and etiology of congenital muscular dystrophy. Neurology, 2008, 71, 312-321.	1.5	83
265	An Examination of Lexical and Sublexical Reading Skills in Children with Neurofibromatosis Type 1. Child Neuropsychology, 2008, 14, 401-418.	0.8	34
266	Cognitive and Psychological Profile of Males With Becker Muscular Dystrophy. Journal of Child Neurology, 2008, 23, 155-162.	0.7	92
267	Why is Î±-Actinin-3 Deficiency So Common in the General Population? The Evolution of Athletic Performance. Twin Research and Human Genetics, 2008, 11, 384-394.	0.3	30
268	A gene for speed: contractile properties of isolated whole EDL muscle from an Î±-actinin-3 knockout mouse. American Journal of Physiology - Cell Physiology, 2008, 295, C897-C904.	2.1	75
269	Cerebrovascular dysplasia in neurofibromatosis type 1. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1165-1170.	0.9	74
270	Correction for Eisenberg et al., Distinctive patterns of microRNA expression in primary muscular disorders. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 399-399.	3.3	1

#	Article	IF	Citations
271	An Actn3 knockout mouse provides mechanistic insights into the association between Â-actinin-3 deficiency and human athletic performance. Human Molecular Genetics, 2008, 17, 1076-1086.	1.4	266
272	Disease Severity and Thin Filament Regulation in M9RTPM3Nemaline Myopathy. Journal of Neuropathology and Experimental Neurology, 2008, 67, 867-877.	0.9	27
273	Bone Mineral Density in Children With Neurofibromatosis Type 1. Journal of Pediatric Orthopaedics, 2008, 28, 791-792.	0.6	1
274	Congenital myopathies. Current Opinion in Neurology, 2008, 21, 569-575.	1.8	66
275	UDP-N-Acetylglucosamine 2-Epimerase/N-Acetylmannosamine Kinase (GNE) Binds to Alpha-Actinin 1: Novel Pathways in Skeletal Muscle?. PLoS ONE, 2008, 3, e2477.	1.1	71
276	Skeletal Muscle Alpha-Actin Diseases. Advances in Experimental Medicine and Biology, 2008, 642, 15-27.	0.8	16
277	Distinctive patterns of microRNA expression in primary muscular disorders. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17016-17021.	3.3	458
278	ACTN3. Exercise and Sport Sciences Reviews, 2007, 35, 30-34.	1.6	118
279	Outcome of noninvasive ventilation in children with neuromuscular disease. Neurology, 2007, 68, 198-201.	1.5	102
280	Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain, 2007, 130, 2725-2735.	3.7	385
281	Mechanisms underlying intranuclear rod formation. Brain, 2007, 130, 3275-3284.	3.7	63
282	Nemaline Myopathy with Exclusively Intranuclear Rods and a Novel Mutation in ACTA1 (Q139H). Neuropediatrics, 2007, 38, 282-286.	0.3	16
283	T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1088-1091.	0.9	87
284	The ACTN3 R577X Polymorphism in East and West African Athletes. Medicine and Science in Sports and Exercise, 2007, 39, 1985-1988.	0.2	100
285	Decreased Bone Mineral Density in Neurofibromatosis Type 1. Journal of Pediatric Orthopaedics, 2007, 27, 472-475.	0.6	83
286	Dystrophinopathy carrier determination and detection of protein deficiencies in muscular dystrophy using lentiviral MyoD-forced myogenesis. Neuromuscular Disorders, 2007, 17, 276-284.	0.3	29
287	Variable penetrance of COL6A1 null mutations: Implications for prenatal diagnosis and genetic counselling in Ullrich congenital muscular dystrophy families. Neuromuscular Disorders, 2007, 17, 547-557.	0.3	33
288	C.I.3 Overview of congenital myopathies. Neuromuscular Disorders, 2007, 17, 832.	0.3	0

#	Article	IF	Citations
289	C.P.1.03 TPM3 is a recurrent cause of congenital fibre type disproportion and is associated with a consistent phenotype. Neuromuscular Disorders, 2007, 17, 834-835.	0.3	0
290	C.P.1.04 Defining diagnostic boundaries for congenital fibre type disproportion. Neuromuscular Disorders, 2007, 17, 835.	0.3	1
291	C.P.3.06 Spectrum of brain changes and genotype-phenotype correlations in secondary dystroglycanopathies. Neuromuscular Disorders, 2007, 17, 871.	0.3	1
292	The pathogenesis ofACTA1-related congenital fiber type disproportion. Annals of Neurology, 2007, 61, 552-561.	2.8	63
293	Intranuclear rod myopathy: molecular pathogenesis and mechanisms of weakness. Annals of Neurology, 2007, 62, 597-608.	2.8	39
294	Molecular consequences of dominant Bethlem myopathy collagen VI mutations. Annals of Neurology, 2007, 62, 390-405.	2.8	66
295	Loss of ACTN3 gene function alters mouse muscle metabolism and shows evidence of positive selection in humans. Nature Genetics, 2007, 39, 1261-1265.	9.4	278
296	Association analysis of the ACTN3 R577X polymorphism and complex quantitative body composition and performance phenotypes in adolescent Greeks. European Journal of Human Genetics, 2007, 15, 88-93.	1.4	165
297	The self-concept of children and adolescents with neurofibromatosis type 1. Child: Care, Health and Development, 2007, 33, 401-408.	0.8	39
298	Myocardial water handling and the role of aquaporins. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 1043-1052.	1.4	45
299	Rippling muscle disease. Journal of Clinical Neuroscience, 2006, 13, 576-578.	0.8	4
300	Autosomal dominant nemaline myopathy with intranuclear rods due to mutation of the skeletal muscle ACTA1 gene: Clinical and pathological variability within a kindred. Neuromuscular Disorders, 2006, 16, 113-121.	0.3	49
301	G.O.2 A clinical and pathological study of congenital fibre type disproportion. Neuromuscular Disorders, 2006, 16, 646.	0.3	0
302	P.I.5 Mutations in SIL1 cause Marinescoâ€“SjÃ¶gren syndrome, a cerebellar ataxia with cataract and myopathy. Neuromuscular Disorders, 2006, 16, 683.	0.3	0
303	P.O.1 Molecular genetic analysis of 6 glycosyltransferases in a large population of dystroglycanopathy patients significantly widens the spectrum of phenotypes resulting from POMT1, POMGnT1 and Fukutin mutations. Neuromuscular Disorders, 2006, 16, 683.	0.3	1
304	P.P.6 04 The clinical and molecular characterisation of calpain deficiency in patients with neuromuscular disorders. Neuromuscular Disorders, 2006, 16, 695.	0.3	0
305	Myosin storage (hyaline body) myopathy: A case report. Neuromuscular Disorders, 2006, 16, 882-886.	0.3	26
306	Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficitâ€“hyperactivity disorder. Developmental Medicine and Child Neurology, 2006, 48, 973.	1.1	203

#	Article	IF	Citations
307	Age-related findings on MRI in neurofibromatosis type 1. Pediatric Radiology, 2006, 36, 1048-1056.	1.1	72
308	SEPN1: Associated with congenital fiber-type disproportion and insulin resistance. Annals of Neurology, 2006, 59, 546-552.	2.8	165
309	Cardiac aquaporin expression in humans, rats, and mice. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H705-H713.	1.5	86
310	Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Human Molecular Genetics, 2006, 15, 129-142.	1.4	66
311	Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attentionâ€deficitâ€hyperactivity disorder. Developmental Medicine and Child Neurology, 2006, 48, 973-977.	1.1	17
312	ACTN3 Genotypes and Obesity-, Power- and Endurance-Related Phenotypes in Adolescent Greeks. Medicine and Science in Sports and Exercise, 2006, 38, S48-S49.	0.2	1
313	An Î±-actinin-3 Knockout Mouse Suffers Increased Sarcomeric Damage from Eccentric Exercise. Medicine and Science in Sports and Exercise, 2006, 38, S123-S124.	0.2	0
314	Mutations in SIL1 cause Marinesco-SjÃ¶gren syndrome, a cerebellar ataxia with cataract and myopathy. Nature Genetics, 2005, 37, 1312-1314.	9.4	232
315	An ?tropomyosin mutation alters dimer preference in nemaline myopathy. Annals of Neurology, 2005, 57, 42-49.	2.8	62
316	A novel X-linked form of congenital fiber-type disproportion. Annals of Neurology, 2005, 58, 767-772.	2.8	26
317	Genes and human elite athletic performance. Human Genetics, 2005, 116, 331-339.	1.8	171
318	The Syntrophin-Dystrobrevin Subcomplex in Human Neuromuscular Disorders. Journal of Neuropathology and Experimental Neurology, 2005, 64, 350-361.	0.9	30
319	The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology, 2005, 65, 1037-1044.	1.5	510
320	Quantitation of long-chain acylcarnitines by HPLC/fluorescence detection: application to plasma and tissue specimens from patients with carnitine palmitoyltransferase-II deficiency. Clinica Chimica Acta, 2005, 352, 81-92.	0.5	29
321	Defining Î±-skeletal and Î±-cardiac actin expression in human heart and skeletal muscle explains the absence of cardiac involvement in ACTA1 nemaline myopathy. Neuromuscular Disorders, 2005, 15, 829-835.	0.3	73
322	Actn3 Genotype Is Not Associated With Elite Endurance Athlete Status In Ethiopians And Kenyans. Medicine and Science in Sports and Exercise, 2005, 37, S472.	0.2	1
323	Genetics of neurocutaneous disorders. , 2004, , 6-23.		0
324	Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. Human Molecular Genetics, 2004, 14, 279-293.	1.4	156

#	Article	IF	Citations
325	Outcome of children with neuromuscular disease admitted to paediatric intensive care. Archives of Disease in Childhood, 2004, 89, 170-175.	1.0	46
326	Evidence for a dominant-negative effect in ACTA1 nemaline myopathy caused by abnormal folding, aggregation and altered polymerization of mutant actin isoforms. Human Molecular Genetics, 2004, 13, 1727-1743.	1.4	89
327	Evaluation of primary haemostasis in people with neurofibromatosis type 1. International Journal of Laboratory Hematology, 2004, 26, 341-345.	0.2	9
328	A gene for speed? The evolution and function of ?-actinin-3. BioEssays, 2004, 26, 786-795.	1.2	197
329	Actin mutations are one cause of congenital fibre type disproportion. Annals of Neurology, 2004, 56, 689-694.	2.8	149
330	C2C12 Co-culture on a fibroblast substratum enables sustained survival of contractile, highly differentiated myotubes with peripheral nuclei and adult fast myosin expression. Cytoskeleton, 2004, 58, 200-211.	4.4	129
331	Expression of aquaporin 1Bin human cardiac and skeletal muscle. Journal of Molecular and Cellular Cardiology, 2004, 36, 655-662.	0.9	63
332	Genotype?phenotype correlations in nemaline myopathy caused by mutations in the genes for nebulin and skeletal muscle ?-actin. Neuromuscular Disorders, 2004, 14, 461-470.	0.3	107
333	Magnetic resonance imaging of muscle in nemaline myopathy. Neuromuscular Disorders, 2004, 14, 779-784.	0.3	98
334	Neurofibromatosis type 1 and optic pathway gliomas Follow-up of 54 patients. Ophthalmology, 2004, 111, 568-577.	2.5	205
335	Social skills of children with neurofibromatosis type 1. Developmental Medicine and Child Neurology, 2004, 46, 553-563.	1.1	4
336	Social skills of children with neurofibromatosis type 1. Developmental Medicine and Child Neurology, 2004, 46, 553-63.	1.1	137
337	Microwave radiation can alter protein conformation without bulk heating. FEBS Letters, 2003, 543, 93-97.	1.3	191
338	ACTN3 Genotype Is Associated with Human Elite Athletic Performance. American Journal of Human Genetics, 2003, 73, 627-631.	2.6	708
339	Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. Neuromuscular Disorders, 2003, 13, 151-157.	0.3	118
340	Deficiency of the syntrophins and Î±-dystrobrevin in patients with inherited myopathy. Neuromuscular Disorders, 2003, 13, 456-467.	0.3	27
341	Clinical course correlates poorly with muscle pathology in nemaline myopathy. Neurology, 2003, 60, 665-673.	1.5	120
342	Single section Western blot. Neurology, 2003, 61, 93-97.	1.5	86

#	Article	IF	Citations
343	Congenital Fiber Type Disproportionâ€"30 Years On. Journal of Neuropathology and Experimental Neurology, 2003, 62, 977-989.	0.9	92
344	Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology, 2003, 60, 1139-1145.	1.5	105
345	Spinal Muscular Atrophy. , 2003, , 553-557.		0
346	Review Article : Cognitive Deficits in Neurofibromatosis 1. Journal of Child Neurology, 2002, 17, 605-612.	0.7	101
347	Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology, 2002, 59, 759-761.	1.5	139
348	Review Article : Neurofibromatosis 1: Clinical Review and Exceptions to the Rules. Journal of Child Neurology, 2002, 17, 613-621.	0.7	55
349	Muscular dystrophies. Current Opinion in Neurology, 2002, 15, 539-544.	1.8	29
350	Primary Î³-sarcoglycanopathy (LGMD 2C): broadening of the mutational spectrum guided by the immunohistochemical profile. Neuromuscular Disorders, 2002, 12, 273-280.	0.3	35
351	Nemaline Myopathy Caused by Mutations in the Muscle Î±-Skeletal-Actin Gene. American Journal of Human Genetics, 2001, 68, 1333-1343.	2.6	144
352	Visual-evoked potentials in the assessment of optic gliomas. Pediatric Neurology, 2001, 24, 44-48.	1.0	30
353	Nemaline myopathy: A clinical study of 143 cases. Annals of Neurology, 2001, 50, 312-320.	2.8	236
354	Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. Human Molecular Genetics, 2001, 10, 1335-1346.	1.4	299
355	The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. Journal of Medical Genetics, 2001, 38, 649-657.	1.5	150
356	A mutation in alpha-tropomyosinslow affects muscle strength, maturation and hypertrophy in a mouse model for nemaline myopathy. Human Molecular Genetics, 2001, 10, 317-328.	1.4	85
357	Congenital muscular dystrophy with primary partial laminin Î±2 chain deficiency: Molecular study. Neurology, 2001, 57, 1319-1322.	1.5	37
358	Neurofibromatosis Type 1. American Journal of Medical Genetics Part A, 2000, 97, 119-127.	2.4	182
359	Mutations in ACTN4, encoding Î±-actinin-4, cause familial focal segmental glomerulosclerosis. Nature Genetics, 2000, 24, 251-256.	9.4	1,124
360	Growth in North American white children with neurofibromatosis 1 (NF1). Journal of Medical Genetics, 2000, 37, 933-938.	1.5	85

#	Article	IF	Citations
361	Cockayne syndrome associated with low CSF 5-hydroxyindole acetic acid levels. Journal of Medical Genetics, 2000, 37, 553-557.	1.5	8
362	â€˜An artefact gone awryâ€™: Identification of the first case of nemaline myopathy by Dr R.D.K. Reye. Neuromuscular Disorders, 2000, 10, 307-312.	0.3	36
363	Neurofibromatosis Type 1. , 2000, 97, 119.		3
364	Mutations in the skeletal muscle Î±-actin gene in patients with actin myopathy and nemaline myopathy. Nature Genetics, 1999, 23, 208-212.	9.4	389
365	A common nonsense mutation results in Î±-actinin-3 deficiency in the general population. Nature Genetics, 1999, 21, 353-354.	9.4	378
366	Spinal muscular atrophy. Journal of Inherited Metabolic Disease, 1999, 22, 545-554.	1.7	33
367	A Novel Syndrome of Episodic Muscle Weakness Maps to Xp22.3. American Journal of Human Genetics, 1999, 65, 1104-1113.	2.6	16
368	Homozygosity for a nonsense mutation in the alpha-tropomyosin slow gene TPM3 in a patient with severe infantile nemaline myopathy. Neuromuscular Disorders, 1999, 9, 573-579.	0.3	105
369	Complex I deficiency in association with structural abnormalities of the diaphragm and brain. Journal of Inherited Metabolic Disease, 1998, 21, 72-73.	1.7	6
370	Clinical aspects of neurofibromatosis 1. European Journal of Paediatric Neurology, 1998, 2, 223-231.	0.7	15
371	Neurofibromatosis 1 in childhood. Seminars in Pediatric Neurology, 1998, 5, 231-242.	1.0	47
372	Abnormalities of dystrophin, the sarcoglycans, and laminin alpha2 in the muscular dystrophies.. Journal of Medical Genetics, 1998, 35, 379-386.	1.5	29
373	Developmental delay, expressive aphasia, hypotonia and dysmorphism in two brothers: an Xâ€linked mental retardation syndrome?. Clinical Genetics, 1998, 54, 443-445.	1.0	0
374	Nemaline myopathy: current concepts. The ENMC International Consortium and Nemaline Myopathy.. Journal of Medical Genetics, 1997, 34, 705-713.	1.5	158
375	Cognitive function and academic performance in neurofibrornatosis 1. Neurology, 1997, 48, 1121-1127.	1.5	270
376	External ophthalmoplegia in neuromuscular disorders: Case report and review of the literature. Neuromuscular Disorders, 1997, 7, 143-151.	0.3	12
377	Neurofibromatosis of the small intestine mesentery in a child with neurofibromatosis type 1. Journal of Pediatric Surgery, 1997, 32, 1783-1785.	0.8	8
378	Recent advances in diagnosis of the childhood muscular dystrophies. Journal of Paediatrics and Child Health, 1997, 33, 195-201.	0.4	9

#	Article	IF	Citations
379	Deficiency of a skeletal muscle isoform of Î±-actinin (Î±-actinin-3) in merosin-positive congenital muscular dystrophy. Neuromuscular Disorders, 1996, 6, 229-235.	0.3	127
380	Oxidative phosphorylation defect associated with primary adrenal insufficiency. Journal of Pediatrics, 1996, 128, 688-692.	0.9	26
381	Cognitive dysfunction as the major presenting feature of Becker's muscular dystrophy. Neurology, 1996, 46, 461-464.	1.5	43
382	MRI findings in children with neurofibromatosis type 1: a prospective study. Pediatric Radiology, 1996, 26, 478-487.	1.1	117
383	Congenital Muscular Dystrophy Associated With Merosin Deficiency. Journal of Child Neurology, 1996, 11, 291-295.	0.7	24
384	Psychological aspects of von Recklinghausen neurofibromatosis (NF1). Journal of Medical Genetics, 1996, 33, 806-806.	1.5	0
385	Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1. British Journal of Haematology, 1995, 89, 582-588.	1.2	20
386	CHARGE association in a child with de novo inverted duplication (14)(q22 â†' q24.3). American Journal of Medical Genetics Part A, 1995, 57, 610-614.	2.4	45
387	Identical twins with Cohen syndrome. American Journal of Medical Genetics Part A, 1995, 58, 54-58.	2.4	27
388	17q inversion involving the neurofibromatosis type one locus in a family with neurofibromatosis type one. American Journal of Medical Genetics Part A, 1995, 60, 312-316.	2.4	6
389	Cerebrovascular complications in Ehlers-Danlos syndrome type IV. Annals of Neurology, 1995, 38, 960-964.	2.8	176
390	Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials. Pediatric Neurology, 1995, 12, 89-90.	1.0	12
391	Lethal neonatal deficiency of carnitine palmitoyltransferase II associated with dysgenesis of the brain and kidneys. Journal of Pediatrics, 1995, 127, 414-420.	0.9	86
392	Neonatal-onset propionic acidemia: Neurologic and developmental profiles, and implications for management. Journal of Pediatrics, 1995, 126, 916-922.	0.9	66
393	Idiopathic hypothalamic dysfunction: a paraneoplastic syndrome?. Lancet, The, 1995, 346, 1298.	6.3	39
394	COGNITIVE FUNCTION AND ACADEMIC PERFORMANCE IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1. Developmental Medicine and Child Neurology, 1995, 37, 427-436.	1.1	110
395	Bilateral Infantile Cataractogenesis in a Patient With Deficiency of Complex I, A Mitochondrial Electron Transport Chain Enzyme. Journal of Pediatric Ophthalmology and Strabismus, 1995, 32, 378-382.	0.3	6
396	Idiopathic Hypothalamic Dysfunction With Dilated Unresponsive Pupils: Report of Two Cases. Journal of Child Neurology, 1994, 9, 320-325.	0.7	40

#	Article	IF	Citations
397	Optic gliomas in neurofibromatosis type 1: Role of visual evoked potentials. Pediatric Neurology, 1994, 10, 117-123.	1.0	58
398	Specific learning disability in children with neurofibromatosis type 1. Neurology, 1994, 44, 878-878.	1.5	182
399	National Neurofibromatosis Foundation International Database. American Journal of Medical Genetics Part A, 1993, 45, 88-91.	2.4	39
400	Postexercise headache in menopausal women. Lancet, The, 1993, 341, 972.	6.3	12
401	Dermoid of cavernous sinus resulting in isolated oculomotor nerve palsy. Pediatric Neurology, 1993, 9, 221-223.	1.0	32
402	Brain-Stem Encephalitis Caused by Epstein-Barr Virus. Journal of Child Neurology, 1993, 8, 40-42.	0.7	22
403	Neurofibromatosis Type 1: Review of the First 200 Patients in an Australian Clinic. Journal of Child Neurology, 1993, 8, 395-402.	0.7	122
404	Hemiplegia due to posterior cerebral artery occlusion.. Stroke, 1993, 24, 1757-1760.	1.0	25
405	FEVER AND SPASTIC QUADRIPARESIS CAUSED BY MYCOPLASMA PNEUMONIAE. Pediatric Infectious Disease Journal, 1992, 11, 129.	1.1	2
406	Pseudoseizures Caused by Hyperventilation Resembling Absence Epilepsy. Journal of Child Neurology, 1990, 5, 288-294.	0.7	23
407	Neurotomes and birth defects: A neuroanatomic method of interpretation of multiple congenital malformations. American Journal of Medical Genetics Part A, 1987, 28, 29-42.	2.4	11
408	Muscle diseases. , 1984, , 194-204.		0
409	Congenital muscular dystrophy. Brain and Development, 1983, 5, 429.	0.6	3
410	Job analysis applied to the special needs of the disabled. Ergonomics, 1981, 24, 889-898.	1.1	10
411	Ergonomics methodologyâ€"an obstacle or promoter for the implementation of ergonomics in industrial practice?. Ergonomics, 1980, 23, 781-795.	1.1	2
412	A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1. Neurological Sciences, 0, , .	0.9	0